ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NIH Seeking Nominations for Review Committees

February 23, 1979

Ruckdeschel To Direct Nevada Cancer Institute

February 6, 2009

In Brief: Cooperative Group Investigators Treat 10 For Every Patient In Protocols – Holland

October 31, 1975

In Brief: McIntyre To Replace Frei As Group Chairman Abeloff, Murphy Nominated For ASCO Presidency

January 26, 1990

Other Agencies Offer Advice; No Money For Oncology Nurse Training

February 24, 1978

Implants Don’t Cause Cancer, Long-Term Study Finds

May 26, 2006